AbbVie plan to withdraw accelerated nods of Imbruvica in US for patients with certain types of blood cancer Ruchika Sharma7 April 2023 3:30 PM ISTIMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc.
Pfizer, Bristol Myers, AbbVie drugs likely to face US price negotiation Ruchika Sharma14 March 2023 3:30 PM ISTNovo Nordisk's diabetes drug Ozempic, prostate cancer treatment Xtandi from Astellas Pharma and Pfizer, and J&J's blood thinner Xarelto are on three...
Janssen bags USFDA nod for IMBRUVICA for chronic graft-versus-host disease treatment Ruchika Sharma28 Aug 2022 12:45 PM ISTChronic graft-versus-host disease is a life-threatening complication that can occur after a stem cell or bone marrow transplant when newly...
AbbVie to pay up to USD 2.37 billion to resolve US opioid claims Ruchika Sharma31 July 2022 2:30 PM ISTNew Delhi: AbbVie Inc has agreed to pay up to $2.37 billion to resolve thousands of U.S. lawsuits against its Allergan unit over the marketing of...
Phase 3 SHINE results show postive results for IMBRUVICA (ibrutinib) in Mantle Cell Lymphoma Ruchika Sharma5 Jun 2022 3:00 PM ISTMCL is a type of aggressive, rare non-Hodgkin lymphoma (NHL) that is incurable and difficult to treat.
Natco Pharma loses patent litigation case over anti-cancer drug Ibrutinib in US Medical Dialogues Team25 Aug 2021 6:12 PM ISTNew Delhi: In a major setback, Natco Pharma has lost a legal battle with Pharmacyclics, a subsidiary of AbbVie over patent of anti-cancer drug...
Natco Pharma gets USFDA nod for Ibrutinib tablets in US Ruchika Sharma12 April 2021 1:52 PM ISTHyderabad: Drugmaker, NATCO Pharma Limited, has recently announced that the company's marketing and distribution partner Alvogen Pine Brook LLC, has...
